Gokhale P C, Barapatre R J, Advani S H, Kshirsagar N A, Pandya S K
Department of Pharmacology, Seth G.S. Medical College, Parel, Bombay, India.
J Cancer Res Clin Oncol. 1993;119(10):569-71. doi: 10.1007/BF01372718.
The case of a female patient with acute lymphoblastic leukaemia and chronic disseminated candidiasis, who was refractory to 1.8 g conventional amphotericin B therapy, is reported. She experienced severe amphotericin-B-related side-effects in spite of pretreatment, but was subsequently successfully treated with 3 g of a small unilamellar liposome formulation of amphotericin B prepared from soya phosphatidylcholine and cholesterol in a 7:3 molar ratio at our institute. The patient experienced minimal side-effects with this preparation, although no pretreatment was given. Liposomal amphotericin B prepared in our institute appears to be a safe and effective therapy for systemic fungal infections. However, large controlled studies are required to determine more precisely the potential of liposomal amphotericin B in the treatment of severe systemic fungal infection.
报告了一例患有急性淋巴细胞白血病和慢性播散性念珠菌病的女性患者，该患者对1.8克常规两性霉素B治疗无效。尽管进行了预处理，她仍出现了严重的两性霉素B相关副作用，但随后在我们研究所接受了3克由大豆磷脂酰胆碱和胆固醇按7:3摩尔比制备的小单层脂质体制剂两性霉素B的治疗，获得成功。尽管未进行预处理，该患者使用这种制剂时副作用极小。我们研究所制备的脂质体两性霉素B似乎是一种治疗系统性真菌感染的安全有效疗法。然而，需要进行大规模对照研究，以更精确地确定脂质体两性霉素B在治疗严重系统性真菌感染中的潜力。
